Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Hypercholesterolemia is a significant cardiovascular risk factor.
• Assessing lipid-lowering drug efficacy in diverse populations is crucial.
• Chinese patients with hypercholesterolemia may have unique responses to treatment.

Purpose of the Study:

• To evaluate the effects of fluvastatin on lipid profiles and apolipoproteins in Chinese patients with hypercholesterolemia.
• To compare the efficacy of two different doses of fluvastatin (20 mg and 40 mg daily).
• To assess the safety and tolerability of fluvastatin in this patient group.

Main Methods:

• A 4-week placebo-controlled study followed by 4 weeks of fluvastatin 20 mg daily and 4 weeks of fluvastatin 40 mg daily.
• Lipid profiles (total cholesterol, triglycerides, LDL-C, HDL-C, VLDL-C) and apolipoproteins (apo B, apo A-I) were measured.
• Patients included those with hypercholesterolemia, hypertension, diabetes, and familial hypercholesterolemia.

Main Results:

• Both fluvastatin doses significantly reduced total cholesterol (-20%), LDL-C (-26%), and apo B (-20%).
• Triglycerides and VLDL-C decreased by approximately 12% with both doses.
• The 40 mg dose increased apo A-I (7%) and HDL-C (10%), with HDL2-C and HDL3-C contributing to the HDL-C increase.

Conclusions:

• Fluvastatin demonstrates significant lipid-lowering effects in Chinese hypercholesterolemic patients.
• The higher dose of fluvastatin (40 mg) also favorably impacts HDL-C levels.
• Fluvastatin is well-tolerated, with only one case of reversible liver enzyme elevation observed.